Establishment Labs

What Establishment Labs does

Establishment Labs Holdings Inc. is a global medical technology company founded in 2004 that develops, manufactures, and sells silicone gel-filled breast implants and related Femtech solutions for breast aesthetics and reconstruction under the Motiva brand. The company is publicly traded on NASDAQ (ticker: ESTA), headquartered in Costa Rica at the Sulàyöm Innovation Campus (LEED Gold-certified, carbon-neutral, MDSAP-certified manufacturing facility), and distributes products in over 100 countries through direct sales to plastic surgeons and hospitals, supplemented by distribution hubs in Belgium (EU) and Brazil. Its portfolio includes Motiva SmoothSilk Round and Ergonomix implants (FDA-approved for augmentation in 2024), the Motiva Flora MRI-conditional tissue expander (FDA-cleared 2023), and the Mia Femtech minimally invasive breast harmonization platform. The portfolio is built on proprietary safety technologies including the Qid RFID implant traceability system, BluSeal visual barrier layer, TrueMonobloc shell-gel construction, and SmoothSilk Ergonomix2 surface, and is supported by over 200 patent applications and 50+ peer-reviewed publications. Customers are plastic and reconstructive surgeons performing breast augmentation, reconstruction after mastectomy, and minimally invasive breast procedures; revenue is generated through hardware sales to these providers with no publicly disclosed pricing.

The company reports full-year 2025 revenue of $211.1 million (up 27.2% year-over-year) and has guided to $264-266 million for 2026, representing another 25-26% growth year. The US market, opened via 2024 FDA approval, contributed approximately 20% augmentation market share within one year of launch. Gross margins have exceeded 70% and the company has achieved three consecutive quarters of positive adjusted EBITDA (Q1 2026: $1.2M), with management targeting full-year cash flow positivity in 2026/2027. In April 2026, the company closed a $300 million senior secured term loan facility with Oaktree Capital Management ($265M refinancing + $35M growth tranche, five-year maturity to 2031), strengthening the balance sheet to fund US and China market expansion, reconstruction label expansion (FDA submission filed December 2025), and continued investment in Mia Femtech commercialization.

Name

Establishment Labs

Legal name

Establishment Labs Holdings Inc.

Website

https://establishmentlabs.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Establishment Labs is a global medical technology company that designs, manufactures, and sells Motiva silicone gel breast implants, MRI-conditional tissue expanders, and the Mia Femtech minimally invasive platform for breast aesthetics and reconstruction, selling B2B to plastic surgeons and hospitals in over 100 countries.

Ownership category

akta.pro rank

Product category

Breast Implants and Women's Health Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)

akta.pro secondary industry

Medical & Dental 3D Printing Services (patient-specific devices, dental labs) (IMAAADAG)

Keywords

• Breast implant manufacturing
• Femtech medical devices
• Women's health aesthetics
• Breast reconstruction devices
• Silicone gel implants

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Breast Implant Sales: Establishment Labs generates revenue through the sale of silicone gel-filled breast implants under the Motiva brand, including SmoothSilk Round, SmoothSilk Ergonomix, JOY, and Flora tissue expander products. Revenue is derived from direct sales to healthcare providers and through distribution partners across 100+ countries.
2. Mia Femtech Platform: Revenue from the Mia Femtech minimally invasive platform and related procedures for breast harmonization, representing an emerging growth opportunity for the company.
3. Preserve Breast Augmentation: Revenue from the Motiva Preserve breast augmentation technique and related educational/training programs.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Establishment Labs designs, manufactures, and sells silicone gel-filled breast implants, MRI-conditional tissue expanders, and minimally invasive breast harmony platforms under the Motiva and Mia Femtech brands. Products are sold through direct enterprise field sales and regional distribution hubs to plastic and reconstructive surgeons, hospitals, and clinics across 100+ countries, with FDA approval in the United States obtained in 2024.

Product overview

Establishment Labs is a global medical technology company offering a portfolio of Femtech solutions for breast health, aesthetics, and reconstruction. The core product line centers on Motiva silicone gel-filled breast implants (SmoothSilk Round and Ergonomix), which received FDA approval in 2024 for augmentation. Supporting products include Motiva Flora MRI-conditional tissue expander for reconstruction, and Mia Femtech for minimally invasive breast harmony. The portfolio is unified by shared safety technologies including Qid RFID traceability, BluSeal visual barrier, TrueMonobloc insertion technology, and SmoothSilk surface. The company operates manufacturing facilities in Costa Rica (Sulàyöm Innovation Campus) and sells products in over 100 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Motiva Implants: Silicone gel-filled breast implants for augmentation and reconstruction
• Motiva Flora
• Mia Femtech
• Motiva JOY
• Preserve

Products and services

• Motiva SmoothSilk Round FDA-approved silicone gel-filled breast implant with SmoothSilk surface technology for primary breast augmentation, reporting a sub-1% device-related complication rate.
• Motiva SmoothSilk Ergonomix FDA-approved ergonomic silicone gel-filled breast implant that adapts to body position, designed to provide natural-looking results with SmoothSilk surface technology.
• Motiva Flora Tissue Expander Next-generation MRI-conditional breast tissue expander with integrated port for two-stage breast reconstruction following mastectomy, positioned as the only regulatory-approved expander in the world with an integrated port that is MRI conditional.
• Mia Femtech Minimally invasive breast harmony procedure using a patented system that shapes the breast in approximately 15 minutes without general anesthesia.
• JOY Ergonomix2 Breast implant combining Motiva's safety attributes with extended warranty cover and patient care programs, featuring the Ergonomix2 surface technology.
• Aesthetic BreastRecon Comprehensive approach enabling women after breast cancer to achieve aesthetic outcomes through standard-of-care breast reconstruction using Motiva products including Motiva Flora tissue expander.
• Motiva Designed Surgeries Tailored surgical approach system for breast augmentation or reconstruction, customized to each patient's unique physique and goals for precise results.

Quantifiable outcome

• Device-related complication rate below 1% vs market average of 10%+
• +3 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• European Distribution Center Motiva BVcoreChannel Partner/ Reseller/ DistributorEuropean Distribution Center Motiva BV operates as the company's EU representative and European distribution hub located in Wommelgem, Belgium, handling distribution across EU and EMEA markets.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Mentor Worldwide (Johnson & Johnson MedTech): Long-standing market leader in breast implants (MemoryGel, MemoryShape) globally and one of the two dominant US suppliers alongside Allergan. Directly competes with Motiva across the same plastic surgeon customer base with overlapping silicone gel implant product lines.
• Allergan Aesthetics (AbbVie): Manufactures Natrelle breast implants and previously Biocell textured implants (withdrawn). Operates the same plastic surgeon channel with far deeper commercial scale and bundled aesthetics portfolio. Establishment Labs' SVP & GM North America was hired directly from Allergan Aesthetics.
• Sientra: US-listed breast implant manufacturer (OPUS silicone gel implants) competing in the same plastic surgery channel. Comparable size and commercial model to Establishment Labs' US business, focused exclusively on breast aesthetics and reconstruction.
• GC Aesthetics: Ireland-based global breast implant and tissue expander manufacturer (PERLE, Round, Anatomical, FIXNIP). Competes head-to-head with Motiva across Europe, LATAM, and APAC in the same plastic surgeon segment.
• Polytech Health & Aesthetics: German manufacturer of silicone breast implants, tissue expanders, and related aesthetic devices. Direct competitor in European and emerging markets; Ivan Bilic (Establishment Labs' SVP OUS) previously held roles at Polytech.
• Ideal Implant: US-focused breast implant company offering structured saline-filled implants. Targets the same plastic surgeon channel with a safety-focused value proposition, though with a fundamentally different product technology than Motiva's silicone gel implants.

Broad incumbents

• Merz Aesthetics: Large aesthetics company (Botox competitor, fillers, devices) that overlaps with Establishment Labs in the broader plastic surgery/aesthetics commercial channel. Several Establishment Labs marketing leaders previously held roles at Merz, indicating overlapping customer relationships.
• Galderma: Global dermatology and aesthetics leader (fillers, toxins, skincare) with overlapping plastic surgeon and dermatologist call points. Does not currently sell breast implants but competes for the same aesthetic procedure economics and customer wallet share.

Others

• Hologic: Women's health medical device company (breast cancer diagnostics, biopsy, surgery equipment). Adjacent to Establishment Labs' breast reconstruction franchise and shares end-customer relationships with breast surgeons, though no direct product overlap.

Emerging players

• Laboratoires Arion: French developer of hydrogel-based breast tissue expanders and other breast surgery devices. Niche competitor in tissue expansion/breast reconstruction space where Establishment Labs' Motiva Flora competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds12 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Establishment Labs